World's Best Scientists 2026 revealed!

Eric L. Simpson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eric L. Simpson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Eric L. Simpson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eric L. Simpson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Eric L. Simpson is affiliated with Oregon Health & Science University in the United States. Their research primarily focuses on the field of medicine with a strong emphasis on dermatology and related areas.

The main fields of study covered in their work include:

  • Medicine

Within this broader domain, their research spans several subfields such as:

  • Dermatology
  • Immunology and Allergy
  • Physiology
  • Rheumatology
  • Immunology

The principal topics of their work are:

  • Dermatology and Skin Diseases
  • Allergic Rhinitis and Sensitization
  • Food Allergy and Anaphylaxis Research
  • Asthma and respiratory diseases
  • Urticaria and Related Conditions
  • Transgenic Plants and Applications
  • IL-33, ST2, and ILC Pathways

Frequent co-authors collaborating with Eric L. Simpson include:

  • Jonathan I. Silverberg
  • Lawrence F. Eichenfield
  • Andrew Blauvelt
  • Amy S. Paller
  • Emma Guttman-Yassky

Their work has been published in several key venues, notable for the number of papers they contributed:

  • Journal of the American Academy of Dermatology
  • British Journal of Dermatology
  • SKIN The Journal of Cutaneous Medicine
  • Journal of Investigative Dermatology
  • Dermatology and Therapy

Some recent significant papers by Eric L. Simpson include:

  • Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1), 2020, The Lancet
  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2), 2021, The Lancet
  • Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2), 2020, British Journal of Dermatology
  • Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis, 2021, JAMA Dermatology
  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis, 2021, New England Journal of Medicine

Best Publications

  • Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study

    Jonathan I. Silverberg;Joel M. Gelfand;David J. Margolis;Mark Boguniewicz

  • Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

    A. Wollenberg;A. Blauvelt;E. Guttman‐Yassky;M. Worm

  • Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

    Eric L. Simpson;Amy S. Paller;Elaine C. Siegfried;Mark Boguniewicz

  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    Emma Guttman-Yassky;Henrique D. Teixeira;Eric L. Simpson;Kim A. Papp

  • Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

    Eric L Simpson;Rodney Sinclair;Seth Forman;Andreas Wollenberg

  • Conjunctivitis in dupilumab clinical trials.

    B. Akinlade;E. Guttman-Yassky;M. de Bruin-Weller;E. L. Simpson

  • Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study

    Jonathan I. Silverberg;Sebastien Barbarot;Abhijit Gadkari;Eric L. Simpson

  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

    Thomas Bieber;Eric L. Simpson;Jonathan I. Silverberg;Diamant Thaçi

  • Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

    Eric L. Simpson;J.‐P. Lacour;L. Spelman;R. Galimberti

  • Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

    Eric L. Simpson;Carsten Flohr;Lawrence F. Eichenfield;Thomas Bieber

  • Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

    Jonathan I. Silverberg;Eric L. Simpson;Jacob P. Thyssen;Melinda J. Gooderham

  • Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population

    Zelma C. Chiesa Fuxench;Julie K. Block;Mark Boguniewicz;John Boyle

  • Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

    Andrew Blauvelt;Henrique D. Teixeira;Eric L. Simpson;Antonio Costanzo

  • Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial

    Emma Guttman-Yassky;Andrew Blauvelt;Lawrence F. Eichenfield;Lawrence F. Eichenfield;Amy S. Paller

  • Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial

    Joanne R Chalmers;Rachel H Haines;Lucy E Bradshaw;Alan A Montgomery

  • Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.

    Eric L. Simpson;Jane R. Parnes;Dewei She;Sarah Crouch

  • What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study.

    Y.A. Leshem;T. Hajar;J.M. Hanifin;E.L. Simpson

  • Persistence of atopic dermatitis (AD): A systematic review and meta-analysis

    Jooho P. Kim;Lucy X. Chao;Eric L. Simpson;Jonathan I. Silverberg

Frequent Co-Authors

Jonathan I. Silverberg
Jonathan I. Silverberg George Washington University Hospital
Lawrence F. Eichenfield
Lawrence F. Eichenfield University of California, San Diego
Mark Boguniewicz
Mark Boguniewicz National Jewish Health
Emma Guttman-Yassky
Emma Guttman-Yassky Icahn School of Medicine at Mount Sinai
Jon M. Hanifin
Jon M. Hanifin Oregon Health & Science University
Lisa A. Beck
Lisa A. Beck University of Rochester Medical Center
David J. Margolis
David J. Margolis University of Pennsylvania
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Hywel C. Williams
Hywel C. Williams University of Nottingham
Joel M. Gelfand
Joel M. Gelfand University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want alternative pathways or supporting degrees, there are several excellent online options to explore. For those interested in the administrative side of healthcare, pursuing an accelerated healthcare administration degree can prepare you for management roles in hospitals and clinics, often in less time than traditional programs.

If patient care is your passion but you’re looking for a flexible or quicker entry point, you might consider the lpn to rn programs without teas test, ideal for licensed practical nurses wanting to become registered nurses without additional standardized testing obstacles.

Medical billing and coding is another essential healthcare field that offers remote job opportunities. Many accredited medical billing and coding schools online with financial aid make it easier to start this career while managing costs.

Lastly, registered nurses aiming to advance their education can benefit from bridge programs such as the rn to np route, helping RNs become nurse practitioners through streamlined online study options.

Best Scientists Citing Eric L. Simpson

Trending Scientists

Recently Published Articles